Overall Prevalence of Anemia 9.3 Percent in August 2021 to August 2023
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 4, 2024 -- During August 2021 to August 2023, the overall prevalence of anemia was 9.3 percent among people aged 2 years and older, according to a December data brief published by the National Center for Health Statistics.
Anne M. Williams, Ph.D., M.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from the August 2021 to August 2023 National Health and Nutrition Examination Survey to estimate the prevalence of anemia in those aged 2 years and older by selected characteristics.
The researchers found that the overall prevalence of anemia was 9.3 percent among people aged 2 years and older during August 2021 to August 2023. Prevalence was higher in females than in males (13.0 versus 5.5 percent). The prevalence of anemia was lowest among children aged 2 to 11 years and highest in adults aged 60 years and older (4.7 and 12.5 percent, respectively). Compared with all other race and Hispanic-origin groups, anemia prevalence was highest in Black non-Hispanic females and Black non-Hispanic males (31.4 and 10.8 percent, respectively). Overall and in males and females aged 2 years and older, the prevalence of anemia decreased with increasing family income.
"Males had a lower prevalence of anemia than females in all race and Hispanic-origin groups; this was also true in all income groups, but not in all age groups," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-06 00:00
Read more
- Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
- 29.4 Percent of U.S. Pharmacies Operating in 2010-2021 Closed by 2021
- Transcranial Direct Current Stimulation Safe, Effective for Tardive Dyskinesia
- About 1 in 10 U.S. Adults Have High Cholesterol
- Most of the World's Cities Lack Enough Trees to Cool, Calm Residents
- Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions